GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zeo ScientifiX Inc (OTCPK:ZEOX) » Definitions » Cyclically Adjusted PB Ratio

Zeo ScientifiX (Zeo ScientifiX) Cyclically Adjusted PB Ratio : (As of May. 01, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Zeo ScientifiX Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Zeo ScientifiX Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Zeo ScientifiX's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zeo ScientifiX Cyclically Adjusted PB Ratio Chart

Zeo ScientifiX Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Zeo ScientifiX Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Zeo ScientifiX's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Zeo ScientifiX's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zeo ScientifiX's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zeo ScientifiX's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Zeo ScientifiX's Cyclically Adjusted PB Ratio falls into.



Zeo ScientifiX Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Zeo ScientifiX's Cyclically Adjusted Book per Share for the quarter that ended in Jan. 2024 is calculated as:

For example, Zeo ScientifiX's adjusted Book Value per Share data for the three months ended in Jan. 2024 was:

Adj_Book=Book Value per Share/CPI of Jan. 2024 (Change)*Current CPI (Jan. 2024)
=-246.185/129.4194*129.4194
=-246.185

Current CPI (Jan. 2024) = 129.4194.

Zeo ScientifiX Quarterly Data

Book Value per Share CPI Adj_Book
201404 -0.040 100.023 -0.052
201407 -0.048 100.520 -0.062
201410 -0.069 100.176 -0.089
201501 -0.084 98.604 -0.110
201504 -0.067 99.824 -0.087
201507 -0.741 100.691 -0.952
201510 0.026 100.346 0.034
201601 -0.566 99.957 -0.733
201604 -0.682 100.947 -0.874
201607 -0.930 101.524 -1.186
201610 -1.503 101.988 -1.907
201701 -2.642 102.456 -3.337
201704 -3.701 103.167 -4.643
201707 -4.863 103.278 -6.094
201710 -6.382 104.070 -7.937
201801 -6.132 104.578 -7.589
201804 -0.280 105.708 -0.343
201807 -0.400 106.324 -0.487
201810 -0.576 106.695 -0.699
201901 -0.651 106.200 -0.793
201904 -0.627 107.818 -0.753
201907 -0.555 108.250 -0.664
201910 -0.622 108.577 -0.741
202001 -0.826 108.841 -0.982
202004 -0.615 108.173 -0.736
202007 -0.490 109.318 -0.580
202010 -0.296 109.861 -0.349
202101 -0.570 110.364 -0.668
202104 -0.460 112.673 -0.528
202107 -0.441 115.183 -0.496
202110 -0.471 116.696 -0.522
202201 -0.572 118.619 -0.624
202204 -0.718 121.978 -0.762
202207 -0.765 125.002 -0.792
202210 0.255 125.734 0.262
202301 0.091 126.223 0.093
202304 -0.019 127.992 -0.019
202307 -0.140 128.974 -0.140
202310 -0.170 129.810 -0.169
202401 -246.185 129.419 -246.185

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Zeo ScientifiX  (OTCPK:ZEOX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Zeo ScientifiX Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Zeo ScientifiX's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Zeo ScientifiX (Zeo ScientifiX) Business Description

Traded in Other Exchanges
N/A
Address
3321 College Avenue, Suite 246, Davie, FL, USA, 33314
Organicell Regenerative Medicine Inc is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine. Its product candidate, Zofinis an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. Zofin is in Phase I/II clinical trials to treat Long COVID and COPD and Osteoarthritis. The company has entered an agreement with CDC to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection.
Executives
Skycrest Holdings, Llc 10 percent owner 1930 HARRISON STREET, SUITE 204, HOLLYWOOD FL 33020
Harry L. Leider director, officer: CEO and Director C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Howard Lawrence Golub officer: Executive Vice President & CSO 23648 SEPTEMBER SUN SQ, ASHBURN VA 20148
Matthew Phillip Sinnreich officer: COO and Acting CEO 4045 SHERIDAN AVENUE, SUITE 239, MIAMI BEACH FL 33139
Steven Jerry Glauser director 1428 BRICKELL AVENUE, SUITE 105, MIAMI FL 33131
Leathem S Stearn director 2306 BAY DRIVE, POMPANO BEACH FL 33062
Charles Luther Bretz director 58 N. CHICAGO ST, 2ND FLOOR, JOLIET IL 60432
Bhupendra Kumar Modi director 6 MARINA BOULEVARD, #63-18, THE SALE @ MARINA BAY U0 018985
Gurvinder Pal Singh director E - 128, FIRST FLOOR, GREATER KAILASH - II, NEW DELHI K7 110048
John F Chiste director
Ryan C Likes officer: Chief Operating Officer 1116 MEADOWBROOK AVE., LOS ANGELES CA 90019
Greyt Ventures, Llc 10 percent owner GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180
Wendy Grey 10 percent owner GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180
Ian T Bothwell 10 percent owner, officer: Chief Financial Officer 77 530 ENFIELD LANE, BLDG D, PALM DESERT CA 92211
Albert Mitrani director, officer: Chief Executive Officer 4045 SHERIDAN AVE., SUITE 239, MIAMI BEACH FL 33140